A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 6, 1998, Pages 517-523

  Kaiser, B ^a   Glusa, E ^a   Hoppensteadt, D A ^b   Breddin, H K ^c   Amiral, J ^d   Fareed, J ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c Intl Inst Thromb and Vasc Dis   (Germany)

^d Serbio   (France)

Author keywords

Anticoagulant actions; ELISA measurement; Low molecular weight heparin; TFPI

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

EID: 0031769522     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199809000-00009     Document Type: Article

References (33)

1. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
2. Broze GJ Jr. Tissue factor pathway inhibitor. Hämostaseologie 1997; 17: 73-77.
3. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-449.
4. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
5. Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996; 26 (suppl 4): 154-165.
6. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insights into its possible mechanism of action. Blood 1988; 71: 335-343.
7. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955.
8. Lindhout T, Franssen J, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-915.
9. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SD, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-8873.
10. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-369.
11. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coag Fibrinol 1995; 6: S57-S64.
12. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol 1994; 5: 819-823.
13. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
14. Valentin S, Ostergaard P, Kristensen H, Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coag Fibrinol 1992; 3: 221-222.
15. Wun TC. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anti-coagulant action between LACI and sulfated polysaccharides. Blood 1992; 79: 430-438.
16. Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coag Fibrinol 1996; 7: 470-476.
17. Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycans. Thromb Res 1994; 75: 609-616.
18. Fareed J, Hoppensteadt DA, Walenga JM. Current perspectives on low molecular weight heparins. Semin Thromb Hemost 1993; 19 (suppl 1): 1-11.
19. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996; 22 (suppl 1): 77-91.
20. Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA. Increased sulphation improves the anti-coagulant activities of heparin sulphate and dermatan sulphate. Biochem J 1987; 248: 889-896.
21. Weichert W, Breddin HK. Effect of low molecular weight heparins on laser-induced thrombus formation in rat mesentcric vessels. Haemostasis 1988; 18 (suppl 3): 55-63.
22. Krupinski K, Breddin HK, Casu B. Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate. Haemostasis 1990; 20: 81-92.
23. Fischer R, Kaiser B, Glusa E. Experimental studies on the antithrombotic effectiveness of a supersulfated low molecular weight heparin in rats [abstract]. Ann Hematol 1996; 72 (suppl I): A 82.
24. Glusa E, Schenk J, Barthel W, Markwardt F, Butti A, Radziwon P, Breddin HK. Effects of single IV and SC injections of a supersulfated low molecular weight heparin on coagulation parameters and on platelet function. Ann Hematol 1994; 68 (suppl II): A54.
25. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of hepann: control by antithrombin III and tissue factor pathway inhibitor. Blood 1996; 87: 2301-2307.
26. Lindahl AK, Abildgaard U, Staalesen R. The anti-coagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168.
27. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hansen TA, Nordøy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 879-885.
28. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
29. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordøy A. Depletion of intravascular pools of tissue-factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-709.
30. Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells - influence of glycosaminoglycans. Thromb Res 1996; 84: 267-278.
31. Harenberg J, Malsch R, Heene DL. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coag Fibrinol 1995; 6: S50-S56.
32. Anderson S, Cohen AT, Melissari E, Scully MS, Kakkar VV. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA. Thromb Haemost 1995; 73: 328-329.
33. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordøy A. Tissue factor pathway inhibitor in complex with low density lipoproteins isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res 1997; 85: 413-425.